Pluristem Therapeutics Inc is incorporated in the state of Nevada on May 11, 2001 under the name A. I. Software Inc. which was changed as of June 30, 2003 to Pluristem Life Systems Inc. On November 26, 2007, the Company's name was changed to Pluristem Therapeutics Inc. The Company is a wholly owned research and development subsidiary in Israel called Pluristem Ltd. The Company operates in one segment, namely, the research, development and commercialization of cell therapeutics and related technologies The Company is a developing standardized cell therapy product from human placenta for the treatment of multiple disorders. The Company develops cell therapy production technologies and products that are derived from the human placenta. Its PLX cells are Adherent Stromal Cells (ASCs) that are expanded using a proprietary three dimensional (3D) process, termed PluriX. PluriX uses a system of stromal cell cultures and substrates to create an artificial 3D environment where placental-derived stromal cells (obtained after birth) can grow. The Company's patented PLX (PLacental eXpanded) cells function as a drug delivery platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. PLX cells are grown using its proprietary 3D micro-environment technology that produces an 'off-the-shelf' product that requires no tissue matching prior to administration. Some of its competitors include Osiris Therapeutics, Aastrom Biosciences, Athersys, Aldagen, Cytori Therapeutics, Mesoblast, and Celgene. The development, manufacturing, and marketing of cell therapy product candidates are subject to the laws and regulations of governmental authorities in the United States and the European Union as well as other countries in which its products will be marketed in the future.